标题
FGFR-TKI resistance in cancer: current status and perspectives
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-02-11
DOI
10.1186/s13045-021-01040-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
- (2020) Melanie A. Krook et al. MOLECULAR CANCER THERAPEUTICS
- Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma
- (2020) Magdalena Rausch et al. BRITISH JOURNAL OF CANCER
- Pemigatinib: First Approval
- (2020) Sheridan M. Hoy DRUGS
- Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors
- (2020) Qian Qin et al. Expert Review of Anticancer Therapy
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
- (2020) Maria Krchniakova et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
- (2020) Chung-Pu Wu et al. Cancers
- Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer
- (2020) Rui Peng et al. Gastric Cancer
- Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
- (2020) Veronica Mollica et al. Cancers
- Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
- (2020) Weiguo Feng et al. Frontiers in Oncology
- Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma
- (2020) Renata Rezende Miranda et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
- (2019) Fiona H Tan et al. OncoTargets and Therapy
- Personalized Prediction of Acquired Resistance to EGFR-Targeted Inhibitors Using a Pathway-Based Machine Learning Approach
- (2019) Young Kim et al. Cancers
- Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
- (2019) Claudia Fumarola et al. Frontiers in Oncology
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
- (2019) Qiming Wang et al. Journal of Hematology & Oncology
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
- (2019) Shuyan Dai et al. Cells
- Fibroblast Growth Factor Receptor Signaling in Skin Cancers
- (2019) Malgorzata Czyz Cells
- Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models
- (2019) Xia Peng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of FGF19-driven hepatocellular cancer
- (2019) Andreas Weiss et al. MOLECULAR CANCER THERAPEUTICS
- Predicting Kinase Inhibitor Resistance: Physics-Based and Data-Driven Approaches
- (2019) Matteo Aldeghi et al. ACS Central Science
- Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells
- (2019) Chun-Han Chen et al. Cancers
- Erdafitinib for the treatment of metastatic bladder cancer
- (2019) Kamaneh Montazeri et al. Expert Review of Clinical Pharmacology
- Future applications of FGF/FGFR inhibitors in cancer
- (2018) Gaia Cristina Ghedini et al. Expert Review of Anticancer Therapy
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- RAS–MAPK Reactivation Facilitates Acquired Resistance inFGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
- (2018) Bruno Bockorny et al. MOLECULAR CANCER THERAPEUTICS
- PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer
- (2018) Abbie E. Fearon et al. Cell Reports
- Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis
- (2018) D. S. Mikhaylenko et al. BIOCHEMISTRY-MOSCOW
- Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547
- (2018) Sjors M. Kas et al. CANCER RESEARCH
- LY2874455 potently inhibits FGFR gatekeeper mutant and overcomes mutation-based resistance
- (2018) Daichao Wu et al. CHEMICAL COMMUNICATIONS
- Recent developments and advances of FGFR as a potential target in cancer
- (2018) Wen-Jun Xue et al. Future Medicinal Chemistry
- Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor
- (2018) Suk-young Lee et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Fibroblast growth factor receptor 5 (FGFR5) is a co-receptor for FGFR1 that is up-regulated in beta-cells by cytokine-induced inflammation
- (2018) Romario Regeenes et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT
- (2018) Molly R Ryan et al. MOLECULAR CANCER RESEARCH
- Acquired JHDM1D-BRAF fusion confers resistance to FGFR inhibition in FGFR2- amplified gastric cancer
- (2018) Hitoshi Sase et al. MOLECULAR CANCER THERAPEUTICS
- Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects
- (2018) Xiaoyun Lu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fibroblast growth factor receptors as treatment targets in clinical oncology
- (2018) Masaru Katoh Nature Reviews Clinical Oncology
- Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity
- (2018) Benny Zhitomirsky et al. Cell Death & Disease
- Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
- (2018) Daniel de Klerk et al. Cancers
- Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074
- (2018) Bernhard Englinger et al. Cells
- A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma
- (2017) Liqin Wang et al. EUROPEAN UROLOGY
- Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas
- (2017) John K. Cowell et al. INTERNATIONAL JOURNAL OF CANCER
- Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer
- (2017) Bernhard Englinger et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β
- (2017) Wen Min Lau et al. MOLECULAR CANCER THERAPEUTICS
- Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
- (2017) Jharna Datta et al. MOLECULAR CANCER THERAPEUTICS
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
- (2017) Michael Michael et al. Targeted Oncology
- 2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
- (2017) Cheng Mo et al. ACS Medicinal Chemistry Letters
- Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study
- (2017) Donglou Liang et al. Drug Design Development and Therapy
- Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
- (2017) Sun Young Kim et al. Oncotarget
- Lysosomes as mediators of drug resistance in cancer
- (2016) Benny Zhitomirsky et al. DRUG RESISTANCE UPDATES
- Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1
- (2016) Kaito Yoza et al. GENES TO CELLS
- Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma
- (2016) Chengfang Li et al. HUMAN PATHOLOGY
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer
- (2016) Feifei Cheng et al. Oncotarget
- Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression
- (2016) Bernhard Englinger et al. Oncotarget
- Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
- (2016) Young Kwang Chae et al. Oncotarget
- Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy
- (2016) S-M Kim et al. Oncogenesis
- Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
- (2016) Daichao Wu et al. PLoS One
- Illuminating the Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance for the FGFR1 Gatekeeper Mutation: The Achilles’ Heel of Targeted Therapy
- (2015) Christal D. Sohl et al. ACS Chemical Biology
- Targeting the lysosome in cancer
- (2015) Shengfu Piao et al. Annals of the New York Academy of Sciences
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB
- (2015) Diego L. Medina et al. NATURE CELL BIOLOGY
- Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
- (2015) Kristy J. Gotink et al. CELLULAR ONCOLOGY
- Novel Mutations in Neuroendocrine Carcinoma of the Breast
- (2015) Daphne Ang et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study
- (2015) Tom D. Bunney et al. EBioMedicine
- Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance
- (2015) Benny Zhitomirsky et al. Oncotarget
- The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors
- (2015) Sara A Byron et al. NEOPLASIA
- DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors
- (2014) Zhifeng Huang et al. ACS Chemical Biology
- Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance
- (2014) N. Javidi-Sharifi et al. CANCER RESEARCH
- Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion
- (2014) S. J. Coleman et al. EMBO Molecular Medicine
- Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells
- (2014) Paulina Grygielewicz et al. Gastric Cancer
- The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
- (2014) Y. Nakanishi et al. MOLECULAR CANCER THERAPEUTICS
- Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells
- (2014) J Wang et al. ONCOGENE
- The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
- (2014) Christiane R. Maroun et al. PHARMACOLOGY & THERAPEUTICS
- Prognostic Value of FGFR Gene Amplification in Patients with Different Types of Cancer: A Systematic Review and Meta-Analysis
- (2014) Jinjia Chang et al. PLoS One
- Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
- (2014) Li Tan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4
- (2014) Julie A. Tucker et al. STRUCTURE
- Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
- (2013) Kai Hung Tiong et al. APOPTOSIS
- Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
- (2013) Joseph M. Gozgit et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Myeloid neoplasms associated with eosinophilia and rearrangement ofPDGFRA,PDGFRB, andFGFR1: a review
- (2013) N. Savage et al. International Journal of Laboratory Hematology
- P-glycoprotein Mediates Drug Resistance via a Novel Mechanism Involving Lysosomal Sequestration
- (2013) Tetsuo Yamagishi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
- (2013) Hideki Terai et al. MOLECULAR CANCER RESEARCH
- Signals from the lysosome: a control centre for cellular clearance and energy metabolism
- (2013) Carmine Settembre et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
- (2013) M. T. Herrera-Abreu et al. Cancer Discovery
- Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
- (2013) Maria Vittoria Dieci et al. Cancer Discovery
- A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
- (2013) K E Ware et al. Oncogenesis
- MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB
- (2012) Jose A. Martina et al. Autophagy
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
- (2012) V Chell et al. ONCOGENE
- High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated
- (2012) Camilla Krakstad et al. PLoS One
- Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers
- (2012) Y Adar et al. Cell Death & Disease
- Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth
- (2012) Fred Harbinski et al. Cancer Discovery
- Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways
- (2011) N. Shukla et al. CLINICAL CANCER RESEARCH
- Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis
- (2011) T. Osawa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Biology of FGFRL1, the fifth fibroblast growth factor receptor
- (2010) Beat Trueb CELLULAR AND MOLECULAR LIFE SCIENCES
- ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug
- (2009) B. Chapuy et al. HAEMATOLOGICA
- Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation
- (2008) S. A. Byron et al. CANCER RESEARCH
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now